Pfizer (NYSE:PFE) Trading Down 1.5% - Time to Sell?

Pfizer Inc. (NYSE:PFE - Get Free Report) traded down 1.5% during mid-day trading on Tuesday . The stock traded as low as $24.72 and last traded at $24.97. 11,670,036 shares were traded during mid-day trading, a decline of 74% from the average session volume of 44,726,215 shares. The stock had previously closed at $25.34.

Analyst Ratings Changes

A number of research firms have recently commented on PFE. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Truist Financial cut their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a report on Wednesday, December 18th. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. UBS Group lowered their price objective on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. Finally, Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. One analyst has rated the stock with a sell rating, seven have given a hold rating, six have given a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $31.92.

Pfizer Stock Down 5.4 %

The firm has a market cap of $130.39 billion, a PE ratio of 16.31, a PEG ratio of 0.64 and a beta of 0.61. The company's 50-day simple moving average is $25.93 and its two-hundred day simple moving average is $26.81. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Remove Ads

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. Pfizer's quarterly revenue was up 24.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.10 EPS. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the company's stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. Quent Capital LLC raised its stake in Pfizer by 15.1% during the first quarter. Quent Capital LLC now owns 12,878 shares of the biopharmaceutical company's stock valued at $326,000 after buying an additional 1,694 shares during the last quarter. Legacy Private Trust Co. increased its holdings in shares of Pfizer by 4.4% during the first quarter. Legacy Private Trust Co. now owns 14,366 shares of the biopharmaceutical company's stock valued at $364,000 after acquiring an additional 600 shares in the last quarter. Central Pacific Bank Trust Division raised its position in shares of Pfizer by 19.4% in the 1st quarter. Central Pacific Bank Trust Division now owns 21,634 shares of the biopharmaceutical company's stock worth $548,000 after purchasing an additional 3,516 shares during the last quarter. Versant Capital Management Inc boosted its stake in Pfizer by 186.0% in the 1st quarter. Versant Capital Management Inc now owns 19,446 shares of the biopharmaceutical company's stock worth $493,000 after purchasing an additional 12,647 shares in the last quarter. Finally, First Hawaiian Bank grew its position in Pfizer by 6.9% during the 1st quarter. First Hawaiian Bank now owns 54,455 shares of the biopharmaceutical company's stock valued at $1,380,000 after purchasing an additional 3,531 shares during the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.